esauce, and thereby swallowed. the entire contents of each namenda xr capsule should be consumed; the dose should not be divided. except when opened and sprinkled on applesauce, as described above, namenda xr should be swallowed whole. namenda xr capsules should not be divided, chewed, or crushed. if a patient misses a single dose of namenda xr, that patient should not double up on the next dose. the next dose should be taken as scheduled. if a patient fails to take namenda xr for several days, dosing may need to be resumed at lower doses and retitrated as described above. 2.2 switching from namenda to namenda xr capsules patients treated with namenda may be switched to namenda xr capsules as follows: it is recommended that a patient who is on a regimen of 10 mg twice daily of namenda be switched to namenda xr 28 mg once daily capsules the day following the last dose of 10 mg namenda. there is no study addressing the comparative efficacy of these 2 regimens. in a patient with severe renal impairment, it is recommended that a patient who is on a regimen of 5 mg twice daily of namenda be switched to namenda xr 14 mg once daily capsules the day following the last dose of 5 mg namenda. 2.3 dosing in patients with renal impairment in patients with severe renal impairment (creatinine clearance of 5 – 29 ml/min, based on the cockcroft-gault equation), the recommended maintenance dose (and maximum recommended dose) is 14 mg/day [see clinical pharmacology ( 12.3 )] .

xr, the proportion of patients in the namenda xr group and the placebo group who discontinued treatment due to adverse reactions was 10% and 6%, respectively. the most common adverse reaction that led to treatment discontinuation in the namenda xr group was dizziness, at a rate of 1.5%. most common adverse reactions the most commonly observed adverse reactions seen in patients administered namenda xr in the controlled clinical trial, defined as those occurring at a frequency of at least 5% in the namenda xr group and at a frequency higher than placebo, were headache, diarrhea and dizziness. table 1 lists adverse reactions that were observed at an incidence of ≥ 2% in the namenda xr group and occurred at a rate greater than placebo. table 1: adverse reactions observed with a frequency of ≥ 2% in the namenda xr group and at a rate greater than placebo adverse r eaction placebo (n=335) % namenda xr 28 mg (n=341) % gastrointestinal disorders diarrhea 4 5 constipation 1 3 abdominal pain 1 2 vomiting 1 2 infections and i nfestations influenza 3 4 investigations weight, increased 1 3 musculoskeletal and c onnective t issue d isorders back pain 1 3 nervous s ystem d isorders headache 5 6 dizziness 1 5 somnolence 1 3 psychiatric d isorders anxiety 3 4 depression 1 3 aggression 1 2 renal and u rinary d isorders urinary incontinence 1 2 vascular d isorders hypertension 2 4 hypotension 1 2 seizure memantine has not been systematically evaluated in patients with a seizure disorder. in clinical trials of memantine, seizures occurred in 0.3% of patients treated with memantine and 0.6% of patients treated with placebo. 6. 2 post m arketing experience the following adverse reactions have been identified during post-approval use of memantine. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. these reactions include: blood and lymphatic system disorders: agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia, thrombotic thrombocytopenic purpura. cardiac disorders: cardiac failure congestive. gastrointestinal disorders: pancreatitis. hepatobiliary disorders: hepatitis. psychiatric disorders: suicidal ideation. renal and urinary disorders: acute renal failure (including increased creatinine and renal insufficiency). skin disorders: stevens johnson syndrome.

rse developmental effects (6 mg/kg) is 2 times the maximum recommended human daily dose (mrhd) of namenda xr (28 mg) on a body surface area (mg/m 2 ) basis. oral administration of memantine to rabbits (0, 3, 10, or 30 mg/kg/day) during the period of organogenesis resulted in no adverse developmental effects. the highest dose tested is approximately 20 times the mrhd of namenda xr on a mg/m 2 basis. in rats, memantine (0, 2, 6, or 18 mg/kg/day) was administered orally prior to and throughout mating and, in females, through the period of organogenesis or continuing throughout lactation to weaning. decreased skeletal ossification in fetuses and decreased body weight in pups were observed at the highest dose tested. the higher no-effect dose for adverse developmental effects (6 mg/kg/day) is 2 times the mrhd of namenda xr on a mg/m 2 basis. oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats from late gestation throughout lactation to weaning, resulted in decreased pup weights at the highest dose tested. the higher no-effect dose (6 mg/kg/day) is approximately 2 times the mrhd of namenda xr on a mg/m 2 basis. 8.2 lactation risk summary there are no data on the presence of memantine in human milk, the effects on the breastfed infant, or the effects of namenda xr on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for namenda xr and any potential adverse effects on the breastfed infant from namenda xr or from the underlying maternal condition. 8. 4 pediatric use safety and effectiveness in pediatric patients have not been established. memantine failed to demonstrate efficacy in two 12-week controlled clinical studies of 578 pediatric patients aged 6-12 years with autism spectrum disorders (asd), including autism, asperger’s disorder and pervasive development disorder - not otherwise specified (pdd-nos). memantine has not been studied in pediatric patients under 6 years of age or over 12 years of age. memantine treatment was initiated at 3 mg/day and the dose was escalated to the target dose (weight-based) by week 6. oral doses of memantine 3, 6, 9, or 15 mg extended-release capsules were administered once daily to patients with weights < 20 kg, 20-39 kg, 40-59 kg and ≥ 60 kg, respectively. in a randomized, 12-week double-blind, placebo-controlled parallel study (study a) in patients with autism, there was no statistically significant difference in the social responsiveness scale (srs) total raw score between patients randomized to memantine (n=54) and those randomized to placebo (n=53). in a 12-week responder-enriched randomized withdrawal study (study b) in 471 patients with asd, there was no statistically significant difference in the loss of therapeutic response rates between patients randomized to remain on full-dose memantine (n=153) and those randomized to switch to placebo (n=158). the overall safety profile of memantine in pediatric patients was generally consistent with the known safety profile in adults [see adverse reactions ( 6.1 )] . in study a, the adverse reactions in the memantine group (n=56) that were reported in at least 5% of patients and at least twice the frequency of the placebo group (n=58) are listed in table 2. table 2: study a commonly reported adverse reactions with a frequency ≥ 5% and twice that of placebo adverse reaction memantine n=56 placebo n=58 cough 8.9% 3.4% influenza 7.1% 3.4% rhinorrhea 5.4% 0% agitation 5.4% 1.7% discontinuations due to a dverse r eaction s a aggression 3.6% 1.7% irritability 1.8% 3.4% a reported adverse reactions leading to discontinuation in more than one patient in either treatment group. the adverse reactions that were reported in at least 5% of patients in the 12-48 week open-label study to identify responders to enroll in study b are listed in table 3. table 3: 12-48 week open label lead-in study to study b commonly reported adverse reactions with a frequency ≥ 5% adverse reaction memantine n=903 headache 8.0% nasopharyngitis 6.3% pyrexia 5.8% irritability 5.4% discontinuations due to a dverse r eaction s a irritability 1.2% aggression 1.0% a at least 1% incidence of adverse reactions leading to premature discontinuation. in the randomized withdrawal study (study b), the adverse reaction in patients randomized to placebo (n=160) and reported in at least 5% of patients and twice that of the full-dose memantine treatment group (n=157) was irritability (5.0% vs 2.5%). juvenile animal study in a juvenile animal study, male and female juvenile rats were administered memantine (15, 30, and 45 mg/kg/day) starting on postnatal day (pnd) 14 through pnd 70. body weights were reduced at 45 mg/kg/day. delays in sexual maturation were noted in male and female rats at doses ≥ 30 mg/kg/day. memantine induced neuronal lesions in several areas of the brain on pnd 15 and 17 at doses ≥ 30 mg/kg/day. behavioral toxicity (decrease percent of auditory startle habituation) was noted for animals in the 45 mg/kg/day dose group. the 15 mg/kg/day dose was considered the no-observed-adverse-effect-level (noael) for this study. in a second juvenile rat toxicity study, male and female juvenile rats were administered memantine (1, 3, 8, 15, 30, and 45 mg/kg/day) starting on postnatal day (pnd) 7 through pnd 70. due to early memantine-related mortality, the 30 and 45 mg/kg/day dose groups were terminated without further evaluation. memantine induced apoptosis or neuronal degeneration in several areas of the brain on pnd 8, 10, and 17 at a dose of 15 mg/kg/day. the noael for apoptosis and neuronal degeneration was 8 mg/kg/day. behavioral toxicity (effects on motor activity, auditory startle habituation, and learning and memory) was noted at doses ≥ 3 mg/kg/day during treatment, but was not seen after drug discontinuation. therefore, the 1 mg/kg/day dose was considered the noael for the neurobehavioral effect in this study. 8.5 geriatric use the majority of people with alzheimer’s disease are 65 years of age and older. in the clinical study of memantine hydrochloride extended-release, the mean age of patients was approximately 77 years; over 91% of patients were 65 years and older, 67% were 75 years and older, and 14% were at or above 85 years of age. the efficacy and safety data presented in the clinical trial sections were obtained from these patients. there were no clinically meaningful differences in most adverse reactions reported by patient groups ≥ 65 years old and < 65 years old. 8.6 renal impairment no dosage adjustment is needed in patients with mild or moderate renal impairment. a dosage reduction is recommended in patients with severe renal impairment [see dosage and administration ( 2.3 ) and clinical pharmacology ( 12.3 )] . 8.7 hepatic impairment no dosage adjustment is needed in patients with mild or moderate hepatic impairment. namenda xr was not studied in patients with severe hepatic impairment [see clinical pharmacology ( 12.3 )] .

g/kg) is 2 times the maximum recommended human daily dose (mrhd) of namenda xr (28 mg) on a body surface area (mg/m 2 ) basis. oral administration of memantine to rabbits (0, 3, 10, or 30 mg/kg/day) during the period of organogenesis resulted in no adverse developmental effects. the highest dose tested is approximately 20 times the mrhd of namenda xr on a mg/m 2 basis. in rats, memantine (0, 2, 6, or 18 mg/kg/day) was administered orally prior to and throughout mating and, in females, through the period of organogenesis or continuing throughout lactation to weaning. decreased skeletal ossification in fetuses and decreased body weight in pups were observed at the highest dose tested. the higher no-effect dose for adverse developmental effects (6 mg/kg/day) is 2 times the mrhd of namenda xr on a mg/m 2 basis. oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats from late gestation throughout lactation to weaning, resulted in decreased pup weights at the highest dose tested. the higher no-effect dose (6 mg/kg/day) is approximately 2 times the mrhd of namenda xr on a mg/m 2 basis.

ts randomized to memantine (n=54) and those randomized to placebo (n=53). in a 12-week responder-enriched randomized withdrawal study (study b) in 471 patients with asd, there was no statistically significant difference in the loss of therapeutic response rates between patients randomized to remain on full-dose memantine (n=153) and those randomized to switch to placebo (n=158). the overall safety profile of memantine in pediatric patients was generally consistent with the known safety profile in adults [see adverse reactions ( 6.1 )] . in study a, the adverse reactions in the memantine group (n=56) that were reported in at least 5% of patients and at least twice the frequency of the placebo group (n=58) are listed in table 2. table 2: study a commonly reported adverse reactions with a frequency ≥ 5% and twice that of placebo adverse reaction memantine n=56 placebo n=58 cough 8.9% 3.4% influenza 7.1% 3.4% rhinorrhea 5.4% 0% agitation 5.4% 1.7% discontinuations due to a dverse r eaction s a aggression 3.6% 1.7% irritability 1.8% 3.4% a reported adverse reactions leading to discontinuation in more than one patient in either treatment group. the adverse reactions that were reported in at least 5% of patients in the 12-48 week open-label study to identify responders to enroll in study b are listed in table 3. table 3: 12-48 week open label lead-in study to study b commonly reported adverse reactions with a frequency ≥ 5% adverse reaction memantine n=903 headache 8.0% nasopharyngitis 6.3% pyrexia 5.8% irritability 5.4% discontinuations due to a dverse r eaction s a irritability 1.2% aggression 1.0% a at least 1% incidence of adverse reactions leading to premature discontinuation. in the randomized withdrawal study (study b), the adverse reaction in patients randomized to placebo (n=160) and reported in at least 5% of patients and twice that of the full-dose memantine treatment group (n=157) was irritability (5.0% vs 2.5%). juvenile animal study in a juvenile animal study, male and female juvenile rats were administered memantine (15, 30, and 45 mg/kg/day) starting on postnatal day (pnd) 14 through pnd 70. body weights were reduced at 45 mg/kg/day. delays in sexual maturation were noted in male and female rats at doses ≥ 30 mg/kg/day. memantine induced neuronal lesions in several areas of the brain on pnd 15 and 17 at doses ≥ 30 mg/kg/day. behavioral toxicity (decrease percent of auditory startle habituation) was noted for animals in the 45 mg/kg/day dose group. the 15 mg/kg/day dose was considered the no-observed-adverse-effect-level (noael) for this study. in a second juvenile rat toxicity study, male and female juvenile rats were administered memantine (1, 3, 8, 15, 30, and 45 mg/kg/day) starting on postnatal day (pnd) 7 through pnd 70. due to early memantine-related mortality, the 30 and 45 mg/kg/day dose groups were terminated without further evaluation. memantine induced apoptosis or neuronal degeneration in several areas of the brain on pnd 8, 10, and 17 at a dose of 15 mg/kg/day. the noael for apoptosis and neuronal degeneration was 8 mg/kg/day. behavioral toxicity (effects on motor activity, auditory startle habituation, and learning and memory) was noted at doses ≥ 3 mg/kg/day during treatment, but was not seen after drug discontinuation. therefore, the 1 mg/kg/day dose was considered the noael for the neurobehavioral effect in this study.

tenth the potency. in vitro studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil, galantamine, or tacrine. 12.3 pharmacokinetics memantine is well absorbed after oral administration and has linear pharmacokinetics over the therapeutic dose range. it is excreted predominantly unchanged in urine and has a terminal elimination half-life of about 60-80 hours. in a study comparing 28 mg once daily namenda xr to 10 mg twice daily namenda, the c max and auc 0-24 values were 48% and 33% higher for the xr dosage regimen, respectively. absorption after multiple dose administration of namenda xr, memantine peak concentrations occur around 9-12 hours post-dose. there is no difference in the absorption of namenda xr when the capsule is taken intact or when the contents are sprinkled on applesauce. there is no difference in memantine exposure, based on c max or auc, for namenda xr whether that drug product is administered with food or on an empty stomach. however, peak plasma concentrations are achieved about 18 hours after administration with food versus approximately 25 hours after administration on an empty stomach. distribution the mean volume of distribution of memantine is 9-11 l/kg and the plasma protein binding is low (45%). elimination metabolism memantine undergoes partial hepatic metabolism. the hepatic microsomal cyp450 enzyme system does not play a significant role in the metabolism of memantine. excretion memantine is excreted predominantly unchanged in the urine and has a terminal elimination half-life of about 60-80 hours. about 48% of administered drug is excreted unchanged in urine; the remainder is converted primarily to three polar metabolites which possess minimal nmda receptor antagonistic activity: the n-glucuronide conjugate, 6-hydroxy-memantine, and 1-nitroso-deaminated memantine. a total of 74% of the administered dose is excreted as the sum of the parent drug and the n-glucuronide conjugate. renal clearance involves active tubular secretion moderated by ph dependent tubular reabsorption. specific populations elderly the pharmacokinetics of memantine in young and elderly subjects are similar. gender following multiple dose administration of memantine hydrochloride 20 mg daily, females had about 45% higher exposure than males, but there was no difference in exposure when body weight was taken into account. renal impairment memantine pharmacokinetics were evaluated following single oral administration of 20 mg memantine hydrochloride in 8 subjects with mild renal impairment (creatinine clearance, clcr, > 50 – 80 ml/min), 8 subjects with moderate renal impairment (clcr 30 – 49 ml/min), 7 subjects with severe renal impairment (clcr 5 – 29 ml/min) and 8 healthy subjects (clcr > 80 ml/min) matched as closely as possible by age, weight and gender to the subjects with renal impairment. mean auc 0- ∞ increased by 4%, 60%, and 115% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. the terminal elimination half-life increased by 18%, 41%, and 95% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. hepatic impairment memantine pharmacokinetics were evaluated following the administration of single oral doses of 20 mg in 8 subjects with moderate hepatic impairment (child-pugh class b, score 7-9) and 8 subjects who were age-, gender-, and weight-matched to the hepatically-impaired subjects. there was no change in memantine exposure (based on cmax and auc) in subjects with moderate hepatic impairment as compared with healthy subjects. however, terminal elimination half-life increased by about 16% in subjects with moderate hepatic impairment as compared with healthy subjects. drug-drug interactions use with cholinesterase inhibitors coadministration of memantine with the ache inhibitor donepezil did not affect the pharmacokinetics of either compound. furthermore, memantine did not affect ache inhibition by donepezil. in a 24-week controlled clinical study in patients with moderate to severe alzheimer’s disease, the adverse reaction profile observed with a combination of memantine immediate-release and donepezil was similar to that of donepezil alone. effect of memantine on the metabolism of other drugs in vitro studies conducted with marker substrates of cyp450 enzymes (cyp1a2, -2a6, -2c9, -2d6, -2e1, -3a4) showed minimal inhibition of these enzymes by memantine. in addition, i n vitro studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome p450 isozymes cyp1a2, -2c9, -2e1 and -3a4/5. no pharmacokinetic interactions with drugs metabolized by these enzymes are expected. pharmacokinetic studies evaluated the potential of memantine for interaction with warfarin and bupropion. memantine did not affect the pharmacokinetics of the cyp2b6 substrate bupropion or its metabolite hydroxybupropion. furthermore, memantine did not affect the pharmacokinetics or pharmacodynamics of warfarin as assessed by the prothrombin inr. effect of other drugs on memantine memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the cyp450 system are not expected to alter the metabolism of memantine. drugs eliminated via renal mechanisms because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (hctz), triamterene (ta), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. however, coadministration of memantine and hctz/ta did not affect the bioavailability of either memantine or ta, and the bioavailability of hctz decreased by 20%. in addition, coadministration of memantine with the antihyperglycemic drug glucovance ® (glyburide and metformin hydrochloride) did not affect the pharmacokinetics of memantine, metformin and glyburide. furthermore, memantine did not modify the serum glucose lowering effect of glucovance ® , indicating the absence of a pharmacodynamic interaction. drugs highly bound to plasma proteins because the plasma protein binding of memantine is low (45%), an interaction with drugs that are highly bound to plasma proteins, such as warfarin and digoxin, is unlikely.

empty stomach. distribution the mean volume of distribution of memantine is 9-11 l/kg and the plasma protein binding is low (45%). elimination metabolism memantine undergoes partial hepatic metabolism. the hepatic microsomal cyp450 enzyme system does not play a significant role in the metabolism of memantine. excretion memantine is excreted predominantly unchanged in the urine and has a terminal elimination half-life of about 60-80 hours. about 48% of administered drug is excreted unchanged in urine; the remainder is converted primarily to three polar metabolites which possess minimal nmda receptor antagonistic activity: the n-glucuronide conjugate, 6-hydroxy-memantine, and 1-nitroso-deaminated memantine. a total of 74% of the administered dose is excreted as the sum of the parent drug and the n-glucuronide conjugate. renal clearance involves active tubular secretion moderated by ph dependent tubular reabsorption. specific populations elderly the pharmacokinetics of memantine in young and elderly subjects are similar. gender following multiple dose administration of memantine hydrochloride 20 mg daily, females had about 45% higher exposure than males, but there was no difference in exposure when body weight was taken into account. renal impairment memantine pharmacokinetics were evaluated following single oral administration of 20 mg memantine hydrochloride in 8 subjects with mild renal impairment (creatinine clearance, clcr, > 50 – 80 ml/min), 8 subjects with moderate renal impairment (clcr 30 – 49 ml/min), 7 subjects with severe renal impairment (clcr 5 – 29 ml/min) and 8 healthy subjects (clcr > 80 ml/min) matched as closely as possible by age, weight and gender to the subjects with renal impairment. mean auc 0- ∞ increased by 4%, 60%, and 115% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. the terminal elimination half-life increased by 18%, 41%, and 95% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. hepatic impairment memantine pharmacokinetics were evaluated following the administration of single oral doses of 20 mg in 8 subjects with moderate hepatic impairment (child-pugh class b, score 7-9) and 8 subjects who were age-, gender-, and weight-matched to the hepatically-impaired subjects. there was no change in memantine exposure (based on cmax and auc) in subjects with moderate hepatic impairment as compared with healthy subjects. however, terminal elimination half-life increased by about 16% in subjects with moderate hepatic impairment as compared with healthy subjects. drug-drug interactions use with cholinesterase inhibitors coadministration of memantine with the ache inhibitor donepezil did not affect the pharmacokinetics of either compound. furthermore, memantine did not affect ache inhibition by donepezil. in a 24-week controlled clinical study in patients with moderate to severe alzheimer’s disease, the adverse reaction profile observed with a combination of memantine immediate-release and donepezil was similar to that of donepezil alone. effect of memantine on the metabolism of other drugs in vitro studies conducted with marker substrates of cyp450 enzymes (cyp1a2, -2a6, -2c9, -2d6, -2e1, -3a4) showed minimal inhibition of these enzymes by memantine. in addition, i n vitro studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome p450 isozymes cyp1a2, -2c9, -2e1 and -3a4/5. no pharmacokinetic interactions with drugs metabolized by these enzymes are expected. pharmacokinetic studies evaluated the potential of memantine for interaction with warfarin and bupropion. memantine did not affect the pharmacokinetics of the cyp2b6 substrate bupropion or its metabolite hydroxybupropion. furthermore, memantine did not affect the pharmacokinetics or pharmacodynamics of warfarin as assessed by the prothrombin inr. effect of other drugs on memantine memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the cyp450 system are not expected to alter the metabolism of memantine. drugs eliminated via renal mechanisms because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (hctz), triamterene (ta), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. however, coadministration of memantine and hctz/ta did not affect the bioavailability of either memantine or ta, and the bioavailability of hctz decreased by 20%. in addition, coadministration of memantine with the antihyperglycemic drug glucovance ® (glyburide and metformin hydrochloride) did not affect the pharmacokinetics of memantine, metformin and glyburide. furthermore, memantine did not modify the serum glucose lowering effect of glucovance ® , indicating the absence of a pharmacodynamic interaction. drugs highly bound to plasma proteins because the plasma protein binding of memantine is low (45%), an interaction with drugs that are highly bound to plasma proteins, such as warfarin and digoxin, is unlikely.

mg/kg/day (6 times the mrhd on a mg/m 2 basis) orally from 14 days prior to mating through gestation and lactation in females, or for 60 days prior to mating in males. 13.2 animal toxicology and/or pharmacology memantine induced neuronal lesions (vacuolation and necrosis) in the multipolar and pyramidal cells in cortical layers iii and iv of the posterior cingulate and retrosplenial neocortices in rats, similar to those which are known to occur in rodents administered other nmda receptor antagonists. lesions were seen after a single dose of memantine. in a study in which rats were given daily oral doses of memantine for 14 days, the no-effect dose for neuronal necrosis was 4 times the maximum recommended human dose (mrhd of 28 mg/day) on a mg/m 2 basis. in acute and repeat-dose neurotoxicity studies in female rats, oral administration of memantine and donepezil in combination resulted in increased incidence, severity, and distribution of neurodegeneration compared with memantine alone. the no-effect levels of the combination were associated with clinically relevant plasma memantine and donepezil exposures. the relevance of these findings to humans is unknown.

hd on a mg/m 2 basis) orally from 14 days prior to mating through gestation and lactation in females, or for 60 days prior to mating in males.

n of change (cibic-plus). the ability of namenda xr to improve cognitive performance was assessed with the severe impairment battery (sib), a multi-item instrument that has been validated for the evaluation of cognitive function in patients with moderate to severe dementia. the sib examines selected aspects of cognitive performance, including elements of attention, orientation, language, memory, visuospatial ability, construction, praxis, and social interaction. the sib scoring range is from 0 to 100, with lower scores indicating greater cognitive impairment. the ability of namenda xr to produce an overall clinical effect was assessed using a clinician’s interview based impression of change that required the use of caregiver information, the cibic-plus. the cibic-plus is not a single instrument and is not a standardized instrument like the adcs-adl or sib. clinical trials for investigational drugs have used a variety of cibic formats, each different in terms of depth and structure. as such, results from a cibic-plus reflect clinical experience from the trial or trials in which it was used and cannot be compared directly with the results of cibic-plus evaluations from other clinical trials. the cibic-plus used in this trial was a structured instrument based on a comprehensive evaluation at baseline and subsequent time-points of four domains: general (overall clinical status), functional (including activities of daily living), cognitive, and behavioral. it represents the assessment of a skilled clinician using validated scales based on his/her observation during an interview with the patient, in combination with information supplied by a caregiver familiar with the behavior of the patient over the interval rated. the cibic-plus is scored as a seven point categorical rating, ranging from a score of 1, indicating “marked improvement” to a score of 4, indicating “no change” to a score of 7, indicating “marked worsening.” the cibic-plus has not been systematically compared directly to assessments not using information from caregivers (cibic) or other global methods. study results in this study, 677 patients were randomized to one of the following 2 treatments: namenda xr 28 mg/day or placebo while still receiving an achei (either donepezil, galantamine, or rivastigmine). effects on severe impairment battery (sib) figure 1 shows the time course for the change from baseline in sib score for the two treatment groups completing the 24 weeks of the study. at 24 weeks of treatment, the mean difference in the sib change scores for the namenda xr 28 mg/achei-treated (combination therapy) patients compared to the patients on placebo/achei (monotherapy) was 2.6 units. using an locf analysis, namenda xr 28 mg/achei treatment was statistically significantly superior to placebo/achei. figure 1 : time course of the change from baseline in sib score for patients completing 24 weeks of treatment figure 2 shows the cumulative percentages of patients from each treatment group who had attained at least the measure of improvement in sib score shown on the x axis. the curves show that both patients assigned to namenda xr 28 mg/achei and placebo/achei have a wide range of responses, but that the namenda xr 28 mg/achei group is more likely to show an improvement or a smaller decline. figure 2 : cumulative percentage of patients completing 2 4 weeks of double-blind treatment with specified changes from baseline in sib scores figure 3 shows the time course for the cibic-plus score for patients in the two treatment groups completing the 24 weeks of the study. at 24 weeks of treatment, the mean difference in the cibic-plus scores for the namenda xr 28 mg/achei-treated patients compared to the patients on placebo/achei was 0.3 units. using an locf analysis, namenda xr 28 mg/achei treatment was statistically significantly superior to placebo/achei. figure 3: time course of the cibic- plus score for patients completing 24 weeks of treatment figure 4 is a histogram of the percentage distribution of cibic-plus scores attained by patients assigned to each of the treatment groups who completed 24 weeks of treatment. figure 4: distribution of cibic-plus ratings at week 24 figure 1: time course of the change from baseline in sib score for patients completing 24 weeks of treatment. figure 2: cumulative percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in sib scores. figure 3: time course of the cibic-plus score for patients completing 24 weeks of treatment. figure 4: distribution of cibic-plus ratings at week 24.

healthcare professional. advise patients and caregivers that namenda xr may cause headache, diarrhea, and dizziness. made in ireland. distributed by: allergan usa, inc. madison, nj 07940 licensed from merz pharmaceuticals gmbh & co. namenda xr ® is a registered trademark of merz pharma gmbh & co kgaa all other trademarks are the property of their respective owners. allergan and its design are trademarks of allergan, inc. patented. see www.allergan.com/patents © 2019 allergan. all rights reserved.

if you: have or have had seizures have or have had problems passing urine have or have had bladder or kidney problems have liver problems have any other medical conditions are pregnant or plan to become pregnant. it is not known if namenda xr will harm your unborn baby. are breastfeeding or plan to breastfeed. it is not known if memantine passes into your breast milk. talk to your doctor about the best way to feed your baby if you take namenda xr. tell your doctor about all the medicines you take , including prescription and non-prescription medicines, vitamins, and herbal supplements. taking namenda xr with certain other medicines may affect each other. taking namenda xr with other medicines can cause serious side effects. especially tell your doctor if you take: other nmda antagonists such as amantadine, ketamine, and dextromethorphan medicines that make your urine alkaline such as carbonic anhydrase inhibitors and sodium bicarbonate ask your doctor or pharmacist for a list of these medicines, if you are not sure. know the medicines you take. keep a list of them to show your doctor and pharmacist when you get a new medicine. how should i take namenda xr? your doctor will tell you how much namenda xr to take and when to take it. your doctor may change your dose if needed. namenda xr may be taken with food or without food. namenda xr capsules may be opened and sprinkled on applesauce before swallowing, but the contents of the entire capsule should be taken and the dose should not be divided. except when opened and sprinkled on applesauce, namenda xr capsules must be swallowed whole and never crushed, divided or chewed. do not use any capsules of namenda xr that are damaged or show signs of tampering. if you are currently taking another formulation of memantine, talk to your healthcare professional about how to switch to namenda xr. if you forget to take one dose of namenda xr, do not double up on the next dose. you should take only the next dose as scheduled. if you have forgotten to take namenda xr for several days, you should not take the next dose until you talk to your doctor. if you take too much namenda xr, call your doctor or poison control center at 1-800-222-1222, or go to the nearest hospital emergency room right away. what are the possible side effects of namenda xr? namenda xr may cause side effects, including: the most common side effects of namenda xr include: headache diarrhea dizziness these are not all the possible side effects of namenda xr. for more information, ask your doctor or pharmacist. call your doctor for medical advice about side effects. you may report side effects to fda at 1-800-fda-1088. how should i store namenda xr? store namenda xr at room temperature between 68°f to 77°f (20°c to 25°c). what are the ingredients in namenda xr? active ingredient: memantine hydrochloride inactive ingredients: sugar spheres, polyvinylpyrrolidone, hypromellose, talc, polyethylene glycol, ethylcellulose, ammonium hydroxide, oleic acid, and medium chain triglycerides keep namenda xr and all medicines out of the reach of children . general information about the safe and effective use of namenda xr : medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. do not take namenda xr for a condition for which it was not prescribed. do not give namenda xr to other people, even if they have the same condition. it may harm them. this patient information leaflet summarizes the most important information about namenda xr. if you would like more information, talk with your doctor. you can ask your doctor or pharmacist for information about namenda xr that was written for healthcare professionals. for more information about namenda xr, go to www.namendaxr.com, or call allergan at 1-800-678-1605. this patient information has been approved by the u.s. food and drug administration. made in ireland distributed by: allergan usa, inc. madison, nj 07940 licensed from merz pharmaceuticals gmbh & co. kgaa namenda xr ® is a registered trademark of merz pharma gmbh & co. kgaa allergan ® and its design are trademarks of allergan, inc. revised: 11/2019 © 2019 allergan. all rights reserved.